Improvement in plasma D-dimer level in severe SARS-CoV-2 infection can be an indicator of fibrinolysis suppression: Case reports
- PMID: 33847623
- PMCID: PMC8052008
- DOI: 10.1097/MD.0000000000025255
Improvement in plasma D-dimer level in severe SARS-CoV-2 infection can be an indicator of fibrinolysis suppression: Case reports
Abstract
Rationale: Fibrinolysis shutdown associated with severe thrombotic complications is a recently recognized syndrome that was previously seldom investigated in patients with severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It presents a unique therapeutic dilemma, as anticoagulation with heparin alone is insufficient to address the imbalance in fibrinolysis. And while the use of fibrinolytic agents could limit the disease severity, it is often associated with bleeding complications. There is a need for biomarkers that will guide the timely stratification of patients into those who may benefit from both anticoagulant and fibrinolytic therapies.
Patient concerns: All 3 patients presented with shortness of breath along with comorbidities predisposing them to severe SARS-CoV-2 infection. One patient (Patient 3) also suffered from bilateral deep venous thrombosis.
Diagnoses: All 3 patients tested positive for SARS-CoV-2 RNA by reverse transcription polymerase chain reaction (RT-PCR) and were eventually diagnosed with respiratory failure necessitating intubation.
Interventions: All 3 patients required mechanical ventilation support, 2 of which also required renal replacement therapy. All 3 patients were also placed on anticoagulation therapy.
Outcomes: In Patients 1 and 2, the initial D-dimer levels of 0.97 μg/ml fibrinogen equivalent units (FEU) and 0.83 μg/ml FEU were only slightly elevated (normal <0.50 μg/ml FEU). They developed rising D-dimer levels to a peak of 13.21 μg/ml FEU and >20.0 μg/ml FEU, respectively, which dropped to 1.34 μg/ml FEU 8 days later in Patient 1 and to 2.94 μg/ml on hospital day 13 in Patient 2. In Patient 3, the D-dimer level on admission was found to be elevated to >20.00 μg/ml FEU together with imaging evidence of thrombosis. And although he received therapeutic heparin infusion, he still developed pulmonary embolism (PE) and his D-dimer level declined to 5.91 μg/ml FEU. Despite "improvement" in their D-dimer levels, all 3 patients succumbed to multi-system organ failure. On postmortem examination, numerous arterial and venous thromboses of varying ages, many consisting primarily of fibrin, were identified in the lungs of all patients.
Lessons: High D-dimer levels, with subsequent downtrend correlating with clinical deterioration, seems to be an indicator of fibrinolysis suppression. These findings can help form a hypothesis, as larger cohorts are necessary to demonstrate their reproducibility.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Oksana Volod, MD, is a consultant for Stago Diagnostica and Haemonetics. No conflict of interest is declared for the remaining authors.
Figures
Similar articles
-
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0. Trials. 2021. PMID: 33691765 Free PMC article.
-
Clinical and laboratory characteristics of patients with novel coronavirus disease-2019 infection and deep venous thrombosis.J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):605-614.e2. doi: 10.1016/j.jvsv.2020.10.006. Epub 2020 Oct 22. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33190816 Free PMC article.
-
Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy.Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):365-373. doi: 10.1161/ATVBAHA.116.308253. Epub 2016 Dec 29. Arterioscler Thromb Vasc Biol. 2017. PMID: 28062504
-
D-dimer - a multifaceted molecule.Horm Mol Biol Clin Investig. 2024 May 9;45(2):75-84. doi: 10.1515/hmbci-2022-0093. eCollection 2024 Jun 1. Horm Mol Biol Clin Investig. 2024. PMID: 38716869 Review.
-
Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.Shock. 2022 Jan 1;57(1):1-6. doi: 10.1097/SHK.0000000000001825. Shock. 2022. PMID: 34172612 Free PMC article. Review.
Cited by
-
The Cause-Effect Dilemma of Hematologic Changes in COVID-19: One Year after the Start of the Pandemic.Hematol Rep. 2022 Mar 28;14(2):95-102. doi: 10.3390/hematolrep14020014. Hematol Rep. 2022. PMID: 35466178 Free PMC article. Review.
-
Role of Fibrinolysis in the Management of Patients with COVID-19 and Thromboembolic Complications: A Review.J Cardiovasc Dev Dis. 2022 Oct 17;9(10):356. doi: 10.3390/jcdd9100356. J Cardiovasc Dev Dis. 2022. PMID: 36286308 Free PMC article. Review.
-
COVID-19: Not a thrombotic disease but a thromboinflammatory disease.Ups J Med Sci. 2024 Jan 22;129. doi: 10.48101/ujms.v129.9863. eCollection 2024. Ups J Med Sci. 2024. PMID: 38327640 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous